21世纪经济报道记者韩利明 小核酸领域再迎重磅BD（商务拓展）交易。 2月23日晚间，科创板创新药企前沿生物（688221.SH）公告，已与葛兰素史克（GSK）达成一项独家授权许可协议，GSK获得公司 两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及商业化权利。 协议显示，其中一款候选药物已进入新药临床试验申请（IND）阶段，另一款为临床前候选药物。前沿生物将负责其中一款产品在中 国的I期临床试验推进，并完成另一款产品的IND支持性研究。 作为交易对价，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，并在两个项目中累计获得最高9.5亿美元的基于成 功开发、监管及商业化里程碑的付款，同时享有两款产品全球净销售额的分级特许权使用费。 有业内人士向21世纪经济报道记者指出，当前全球小核酸领域交易持续升温，这笔近10亿美元合作有望改善前沿生物现金流、支撑 研发与平台升级，成为其2020年上市以来持续亏损背景下的重要发展拐点，"不过相较于确定性首付款，后续里程碑兑现情况需持续 跟踪"。 受此利好消息提振，作为春节假期后的首个交易日，前沿生物股价在2月24日早盘高开，截至午间休盘报24.5 ...

Core Viewpoint - The company announced significant progress in the Phase III clinical trial of iza-bren for locally advanced or metastatic triple-negative breast cancer, with the independent data monitoring committee recommending early regulatory submission based on interim analysis results [1] Group 1: Clinical Trial Progress - The topline data indicates that iza-bren significantly extends progression-free survival (PFS) and overall survival (OS), achieving both primary endpoints [1] - This marks the third Phase III clinical trial where the dual antibody ADC has reached its primary endpoints [1] Group 2: Regulatory Status - As of now, iza-bren has seven indications included in the breakthrough therapy list by the National Medical Products Administration (NMPA) and one indication by the U.S. Food and Drug Administration (FDA) [2] - Two indications for iza-bren, targeting locally advanced or metastatic nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma, have had their New Drug Applications (NDA) accepted by the NMPA and are in the priority review process [2] Group 3: Development and Market Considerations - The company emphasizes that drug registration requires completion of relevant clinical trials and approval from the NMPA before market launch, highlighting the lengthy and complex nature of the drug development process [2] - The company will actively promote the aforementioned research projects and comply with information disclosure obligations regarding project progress [2]

五震荡走低，险守二十天线。恒指随外围低开 132 港股回顾 点，跌幅随即扩大至 247 点，低见 23730 点，其后跌幅 一度收窄至仅 20 点，午后大盘走势偏软，尾盘沽压再 度扩大。截至收盘，恒指收报 23831 点，下跌 145 点或 0.61%；国指收报 9656 点，下跌 47 点或 0.49%，大市 成交进一步减至 827.99 亿。港股通录得净流入资金 4.84 亿，其中港股通(沪)净流入 2.83 亿，港股通(深)净 流入 2.01 亿。板块方面，本地地产、软件、5G 概念板 块跌幅靠前；黄金股逆市走强。 周一港股三大指数全天强势震荡，恒生指数收涨 2.53%报 27081.91 点，恒生科技指数涨 3.34%报 5385.35 点，恒生中国企业指数涨 2.65%报 9197.38 点。大市成交 1730 亿港元。科技龙头、 半导体、有色股表现亮眼，紫金矿业、美团、中 芯国际涨超 5%，涨幅位居恒指成分股前列。新能 源汽车股普涨，蔚来涨近 6%，比亚迪股份涨近 5%。行业方面，恒生原材料业指数大涨 4.27%， 赣锋锂业涨超 8%，紫金黄金国际、五矿资源涨近 7%。大模型概念股回落，智谱跌近 ...

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任 何投资建议。 | 肿瘤/肿瘤免疫 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 项目 (合作方) | 靶点 | 适应症 | 地区 | 早期发现 | 临床前 | IND | 一期 | 二期 | 三期 | BLA | | 新一代免疫肿瘤治疗单抗 | | | | | | | | | | | | Porustobart (HBM4003) | CTLA-4 | ◆ 黑色素瘤 | 全球 | | | | | | | | | | | ◆ 结直肠癌 | 全球 | | | | | | | | | | | ◆ 肝细胞癌 | 全球 | | | | | | | | | | | ◆ 神经内分泌癌 | 全球 | | | | | | | | | *. | | | | | | | | | | | 药融圈监测显示：和铂医药与海外初创新药公司Solstice Oncology ...

Group 1 - Novo Nordisk's new weight loss drug CagriSema showed a weight reduction of 23% over 84 weeks, which is less effective than Eli Lilly's drug tirzepatide, which achieved a 25.5% reduction [2] - Following the announcement, Novo Nordisk's stock plummeted over 16%, marking its lowest point since June 2021 and erasing all gains from the launch of its previous weight loss drug, semaglutide [2] - The year 2026 is critical for Novo Nordisk as its semaglutide patent is set to expire in China, leading to the potential entry of numerous generic competitors [2] Group 2 - Analysts indicate that CagriSema is expected to contribute significantly to Novo Nordisk's growth, with estimates suggesting it could account for 60% of the company's future growth [3] - The failure of the clinical data for CagriSema is viewed as a major setback that may dampen demand and weaken long-term sales expectations for Novo Nordisk [3] - CagriSema combines the components Cagrilintide and semaglutide, administered via weekly injections [3] Group 3 - Since reaching its peak market value in 2024, Novo Nordisk has seen a decline of over $470 billion, losing all gains from the launch of semaglutide [4] - Eli Lilly's stock surged following the weak clinical data from Novo Nordisk, bringing its market value close to $1 trillion, with expectations of continued growth in demand for tirzepatide [4] - Eli Lilly plans to launch an oral weight loss drug, orforglipron, in the second quarter of this year, intensifying competition with Novo Nordisk's oral semaglutide [4]

Core Insights - 2026 is a critical year for Novo Nordisk as its semaglutide market share faces pressure from competitors led by Eli Lilly [1][2] - Novo Nordisk's new weight loss drug CagriSema showed a weight loss of 23% in a head-to-head trial against Eli Lilly's tirzepatide, which achieved 25.5% [1] - Following the disappointing trial results, Novo Nordisk's stock plummeted over 16%, erasing all gains since the launch of semaglutide [1][3] Company Developments - CEO Mike Doustdar aims to navigate the company through this "crisis" by pushing the new generation weight loss therapy to market [2] - Analysts indicate that CagriSema is crucial for Novo Nordisk's growth, with expectations that 60% of the company's future growth will come from this drug [2] Market Dynamics - CagriSema combines Cagrilintide and GLP-1 component semaglutide, administered weekly [3] - Since reaching its peak market value in 2024, Novo Nordisk has lost over $470 billion in market capitalization, erasing all gains from the launch of semaglutide [3] - Eli Lilly's stock surged following Novo Nordisk's weak clinical data, bringing its market value close to $1 trillion, with expectations for continued growth in tirzepatide demand [3]

协议约定，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，后续还可累计获得最高 9.5亿美元的开发、监管及商业化里程碑付款，并享有两款产品全球净销售额的分级特许权使用费。 分工方面，前沿生物负责一款产品在中国的I期临床试验推进，并完成另一款产品的IND支持性研究， 葛兰素史克则主导两款产品之后所有的全球临床开发、监管申报及商业化活动。 2月23日晚，前沿生物发布公告称，公司已与跨国制药巨头葛兰素史克（GSK）签署独家授权许可协 议。根据该协议，葛兰素史克将获得两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及 商业化权利，其中一款候选药物已进入新药临床试验申请（IND）阶段，另一款为临床前候选药物。 前沿生物表示，合作将改善公司现金流、优化财务结构，为核心管线研发提供资金保障，同时借助葛兰 素史克的全球资源加速管线国际化转化，并为后续推进产品商业化、拓展全球合作奠定坚实基础。 根据公司2025年业绩预告，公司预计实现营业收入1.4亿元-1.45亿元，同比增长8.13%-11.99%，主要来 自抗HIV创新药艾可宁、代理产品缬康韦及获批的远红外治疗贴的销售收入。同期研发费用预计1. ...

默沙东宣布，将分拆业务为两部分，为以重磅药物Keytruda为首的癌症业务创建一个独立的部门，同时 将其非肿瘤治疗业务单独划分出来。目前，Keytruda已获批准用于多种癌症，是全球最畅销的处方药。 该疗法在2025年创造超过300亿美元的收入，占公司总收入的近一半。默克早前警告指，由于几款传统 药物即将失去专利保护期并面临 仿制药的压力，公司的销售额和利润将低于预期。（格隆汇） ...

【国泰海通医药】诺和诺德REDEFINE 4研究（CagriSema头对头Tirzepatide）数据解读电话会要点速递 【国泰海通医药】诺和诺德REDEFINE 4研究（CagriSema头对头Tirzepatide）数据解读电话会要点速递 REDEFINE 4研究设计和结果 两组表现出的耐受性与此前研究中看到的总体一致。 （3） 为什么68周（REDEFINE 1研究 -20.4%ITT/-22.7%PP）延长到84周CagriSema减重效果基本没有提升： REDEFINE 1研究中的经验教训并没有全部纳入REDEFINE 4研究。 但在REDEFINE 11研究中，充分考虑了这些经验教训，CagriSema完整的减重潜力将在该项研究中得到验证。 （1） 试验用药时长为84周，vs REDIFINE 1/2研究的68周 （2） 主要终点是CagriSema 2.4mg/2.4mg与 Tirzepatide 15mg在84周减重效果的非劣性 （3） Open label设计：所有试验参与者知 REDEFINE 4研究设计和结果 若ITT分析，则20.3%vs 23.6%），未达到非劣性目标（公司未披露非劣 ...

肥胖世界ObesityWorld . 以下文章来源于肥胖世界ObesityWorld ，作者肥胖世界 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 多受体激动剂在治疗2型糖尿病患者的高血糖和肥胖症方面展现出改善短期及长期健康结局的潜力。LY3437943作为一种创新型三联激动剂 肽，同时针对葡萄糖依赖性促胰岛素多肽(GIP)、胰高血糖素样肽-1(GLP-1)及胰高血糖素三种受体发挥强效作用，专为2型糖尿病和肥胖症治 疗而设计。 近期《柳叶刀》刊发的12周研究评估了LY3437943在2型糖尿病患者中的安全性与药理特性。结果令人振奋：该药物在12周治疗周期内不仅显 著优化血糖控制，还实现明显减重效果，同时保持与现有肠促胰岛素类药物相当的安全性表现。 这项随机、双盲、安慰剂对照的概念验证1b期试验采用多剂量递增设计，于2019年12月至2020年12月期间在美国4个研究中心进行。研究纳入 72名符合条件的成年患者，这些患者均患有2型糖尿病至少3个月，糖化血红蛋白(HbA1c)值介于7.0%10.5%，体重指 ...